Aligos Therapeutics (ALGS) Stock: Buy, Sell, or Hold?
ALGS - Aligos Therapeutics, Inc. Common Stock
$4.86
-0.53 (-9.83%)
▼
5d:
-8.99%
30d:
-6.0%
90d:
-7.95%
WAIT
LOW Confidence
Analysis Updated: Oct 16, 2026 12:00 AM ET
Earnings: Nov 05, 2026
17d
Get Alerted When ALGS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ALGS shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ALGS shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: ALGS is currently trading at $4.86, which is considered oversold relative to its 30-day fair value range of $5.17 to $5.58.
Technical Outlook: Technically, ALGS is showing sideways momentum. The price is currently testing key support at $4.86. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 9.8% recently.
Market Sentiment: ALGS scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $52.38 (+977.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ALGS is showing sideways momentum. The price is currently testing key support at $4.86. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 9.8% recently.
Market Sentiment: ALGS scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $52.38 (+977.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$5.17 -
$5.58
Company Quality Score
29/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (20/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-9.8%)
- BULLISH: Trading 977.7% below Wall St target ($52.38)
- WARNING: Composite score 29/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$5.17 -
$5.58
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$4.86
Resistance Level
$5.65
Current Trend
Sideways
Technical data as of
Oct 16, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.93
Wall Street Target
$52.38
(+977.7%)
Revenue Growth (YoY)
2778.5%
Profit Margin
-241.0%
Share & Embed Analysis
Last updated: October 18, 2026 11:32 AM ET
Data refreshes hourly during market hours. Next update: 12:32 PM
Data refreshes hourly during market hours. Next update: 12:32 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ALGS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RVMD
Revolution Medicines Inc |
STRONG BUY
24 analysts |
$258 | 48 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
21 analysts |
$95 | 58 HOLD |
|
OCUL
Ocular Therapeutix Inc |
STRONG BUY
12 analysts |
$26 | 75 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$72 | 43 HOLD |
|
JANX
Janux Therapeutics Inc |
STRONG BUY
18 analysts |
$36 | 53 HOLD |
